---
title: "Analyst Reaffirms Buy on Novanta, Citing Accretive Riverpoint Medical Acquisition and Enhanced Growth Profile"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289837251.md"
description: "William Blair analyst Brian Drab reaffirmed a Buy rating on Novanta (NOVT), citing the accretive acquisition of Riverpoint Medical. The deal is expected to boost adjusted EPS, revenue growth, and margins. Drab highlighted favorable deal structure and management confidence in achieving 2027 payment milestones. Robert W. Baird also maintained a Buy rating with an $180 price target."
datetime: "2026-06-15T23:25:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289837251.md)
  - [en](https://longbridge.com/en/news/289837251.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289837251.md)
generator: "portal-rs"
---

# Analyst Reaffirms Buy on Novanta, Citing Accretive Riverpoint Medical Acquisition and Enhanced Growth Profile

William Blair analyst Brian Drab has maintained their bullish stance on NOVT stock, giving a Buy rating on June 9.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Brian Drab has given his Buy rating due to a combination of factors tied to Novanta’s planned acquisition of Riverpoint Medical. He views the deal as strategically attractive, noting that Riverpoint should immediately enhance adjusted earnings per share while also lifting Novanta’s overall revenue growth, gross margin, and EBITDA margin profile.

Drab also emphasizes the favorable deal structure and outlook, highlighting management’s strong confidence that the performance milestones triggering the 2027 payment will be achieved. In his view, this transaction offers a compelling blend of strategic fit, financial strength, and valuation support, reinforcing a positive stance on Novanta’s shares.

Drab covers the Industrials sector, focusing on stocks such as Generac Holdings, nVent Electric, and Xometry. According to TipRanks, Drab has an average return of 38.1% and a 73.98% success rate on recommended stocks. 

In another report released on June 9, Robert W. Baird also maintained a Buy rating on the stock with a $180.00 price target.

### Related Stocks

- [NOVT.US](https://longbridge.com/en/quote/NOVT.US.md)
- [GNRC.US](https://longbridge.com/en/quote/GNRC.US.md)
- [NVT.US](https://longbridge.com/en/quote/NVT.US.md)
- [XMTR.US](https://longbridge.com/en/quote/XMTR.US.md)
- [NOVTU.US](https://longbridge.com/en/quote/NOVTU.US.md)

## Related News & Research

- [Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 | NOVT Stock News](https://longbridge.com/en/news/297369804.md)
- [$1000 Invested In Novanta 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295851073.md)
- [39,140 Shares in Novanta Inc. $NOVT Acquired by Summit Creek Advisors LLC](https://longbridge.com/en/news/296339528.md)
- [Hubbell Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/297191681.md)
- [Novanta completes acquisition of Riverpoint Medical](https://longbridge.com/en/news/293928249.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**